Genomictree Inc.
228760
Rangering i aksjer
#18734
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
Aksjekurs
$7.00
Markedsverdi
$171.81M
Endring (1 dag)
6.44%
Endring (1 år)
-47.27%
Land
KR
Handel Genomictree Inc. (228760)
Kategori
Healthcare
Aksjeprishistorikk for Genomictree Inc. (228760)
Høyeste sluttskurs: $7.30 den 2026-10-01
Laveste sluttskurs: $3.98 den 2017-04-01
Laveste sluttskurs: $3.98 den 2017-04-01
Aksjeprishistorikk for Genomictree Inc. fra 2017 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -34.69% |
| 2025 | 31.68% |
| 2024 | 6.73% |
| 2023 | 91.06% |
| 2022 | -34.74% |
| 2021 | -21.56% |
| 2020 | -30.26% |
| 2019 | -19.05% |
| 2018 | 267.23% |
| 2017 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $535.90 | 25.67% |
US
|
|
| $184.77 | 588.14% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $881.33 | 8.25% |
NL
|
